We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Nixes Cornerstone Low-Sodium Drug, Asks for More Clinical Info
FDA Nixes Cornerstone Low-Sodium Drug, Asks for More Clinical Info
November 2, 2012
The FDA has shot down Cornerstone Therapeutics’ low-sodium drug lixivaptan for both its proposed indications.